Page last updated: 2024-11-03

propofol and Brain Disorders

propofol has been researched along with Brain Disorders in 22 studies

Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.
propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.

Research Excerpts

ExcerptRelevanceReference
"The increment of GABAergic inhibitory activity, the reduction of metabolic rate and oxygen consumption induced by propofol on the neuronal components of brain structures, and its antioxidant potential have supported the possible beneficial effects of this drug against brain damage elicited by cerebral ischemia."7.69Effects of propofol on alterations of multineuronal activity of limbic and mesencephalic structures and neurological deficit elicited by acute global cerebral ischemia. ( Antonio-Ocampo, A; Cervantes, M; Chávez-Carrillo, I; Contreras-Gomez, A; Ruelas, R, 1995)
"We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam."3.81Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015)
"The increment of GABAergic inhibitory activity, the reduction of metabolic rate and oxygen consumption induced by propofol on the neuronal components of brain structures, and its antioxidant potential have supported the possible beneficial effects of this drug against brain damage elicited by cerebral ischemia."3.69Effects of propofol on alterations of multineuronal activity of limbic and mesencephalic structures and neurological deficit elicited by acute global cerebral ischemia. ( Antonio-Ocampo, A; Cervantes, M; Chávez-Carrillo, I; Contreras-Gomez, A; Ruelas, R, 1995)
"This study compares the effects of propofol and fentanyl/N2O on spontaneous brain electrical activity, neurologic outcome, and neuronal damage due to incomplete cerebral ischemia in rats."3.68The effects of propofol on brain electrical activity, neurologic outcome, and neuronal damage following incomplete ischemia in rats. ( Albrecht, RF; Hoffman, WE; Kochs, E; Schulte am Esch, J; Thomas, C; Werner, C, 1992)
"Propofol was added during the OGD phase of the model."1.35Propofol inhibits aquaporin 4 expression through a protein kinase C-dependent pathway in an astrocyte model of cerebral ischemia/reoxygenation. ( Pan, CF; Xiong, XX; Zheng, YY; Zhu, SM, 2009)
"Propofol has been shown to protect against neuronal damage induced by brain ischaemia in small animal models."1.33A moderate dose of propofol and rapidly induced mild hypothermia with extracorporeal lung and heart assist (ECLHA) improve the neurological outcome after prolonged cardiac arrest in dogs. ( Ichinose, K; Okamoto, T; Sugita, M; Taguchi, H; Takeya, M; Tanimoto, H; Tashiro, M; Terasaki, H, 2006)
"Propofol is an intravenous anesthetic agent with a short half-life allowing rapid recovery; it has cerebral hemodynamic effects similar to those of thiopental."1.29[Use of propofol in intracranial surgery in 83 consecutive patients]. ( Borgeat, A; Gaggero, G; Ravussin, P; Wilder-Smith, O, 1994)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.55)18.7374
1990's9 (40.91)18.2507
2000's8 (36.36)29.6817
2010's2 (9.09)24.3611
2020's2 (9.09)2.80

Authors

AuthorsStudies
Umaba, C1
Mineharu, Y1
Liang, N1
Mizota, T1
Yamawaki, R1
Ueda, M1
Yamao, Y1
Nankaku, M1
Miyamoto, S1
Matsuda, S1
Inadomi, H1
Arakawa, Y1
Wu, M1
Yin, X1
Chen, M1
Liu, Y1
Zhang, X1
Li, T1
Long, Y1
Wu, X1
Pu, L1
Zhang, M1
Hu, Z1
Ye, L1
Villalba Martínez, G1
Fernández-Candil, JL1
Vivanco-Hidalgo, RM1
Pacreu Terradas, S1
León Jorba, A1
Arroyo Pérez, R1
Zhao, CH1
Li, GH1
Wang, Q1
Zhao, B1
Wang, ZB1
Morota, S1
Månsson, R1
Hansson, MJ1
Kasuya, K1
Shimazu, M1
Hasegawa, E1
Yanagi, S1
Omi, A1
Uchino, H1
Elmér, E1
Zhu, SM1
Xiong, XX1
Zheng, YY1
Pan, CF1
Iwata, T1
Inoue, S1
Kawaguchi, M1
Takahashi, M1
Sakamoto, T1
Kitaguchi, K1
Furuya, H1
Sakaki, T1
Saito, S1
Kadoi, Y1
Nihishara, F1
Aso, C1
Goto, F1
Schmitz, B1
Nimsky, C1
Wendel, G1
Wienerl, J1
Ganslandt, O1
Jacobi, K1
Fahlbusch, R1
Schüttler, J1
Ichinose, K1
Okamoto, T1
Tanimoto, H1
Taguchi, H1
Tashiro, M1
Sugita, M1
Takeya, M1
Terasaki, H1
Ikeda, Y1
Fudickar, A1
Tonner, PH1
Mihaljovic, Z1
Dellien, C1
Weiler, N1
Scholz, J1
Bein, B1
Newman, MF2
Murkin, JM2
Roach, G1
Croughwell, ND1
White, WD1
Clements, FM1
Reves, JG1
Gaggero, G1
Ravussin, P1
Borgeat, A1
Wilder-Smith, O1
Cervantes, M1
Ruelas, R1
Chávez-Carrillo, I1
Contreras-Gomez, A1
Antonio-Ocampo, A1
Roach, GW1
Martzke, J1
Ruskin, A1
Li, J1
Guo, A1
Wisniewski, A1
Mangano, DT1
Gritsaenko, IuM1
Kochs, E1
Hoffman, WE1
Werner, C1
Thomas, C1
Albrecht, RF1
Schulte am Esch, J1
Merlo, F1
Demo, P1
Lacquaniti, L1
Tricarico, L1
Faccin, G1
Irone, M1
Bone, ME1
Bristow, A1
Mele, D1
Consoletti, L1
Lattanzio, A1
Carrillo, E1
Mazzarella, B1
Mastronardi, P1
Cafiero, T1
Gargiulo, G1
Frangiosa, A1
Stella, L1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964]550 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.27
Placebo-0.89

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.57
Placebo0.16

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery

Interventionunits on a scale (Mean)
Lidocaine0.09
Placebo0.07

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

Interventionunits on a scale (Mean)
Lidocaine0.07
Placebo0.07

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine6.3
Placebo6.96

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-10.98
Placebo-11.67

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.07

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.04

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.02
Placebo-0.02

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.04
Placebo-0.01

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.71
Placebo-1.16

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine1.23
Placebo-0.49

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.20
Placebo0.03

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.95
Placebo1.59

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-6.70
Placebo-6.39

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-7.12
Placebo-6.31

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.39
Placebo-1.48

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-0.67
Placebo-0.8

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.46
Placebo-1.02

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-3
Placebo-3.21

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.15
Placebo-0.31

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine2.46
Placebo2.1

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

InterventionParticipants (Count of Participants)
Lidocaine87
Placebo83

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year

,
Interventionunits on a scale (Mean)
1 year Change Work Activities1 year Change General health perception
Lidocaine-1.37-0.28
Placebo-1.42-0.43

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks

,
Interventionunits on a scale (Mean)
6-Week Change Work activities6-Week Change General health perception
Lidocaine2.71-0.004
Placebo3-0.03

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.150.02-0.73-0.10
Placebo-0.43-0.73-0.400.19

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-4.22-2.46-0.341.21
Placebo-0.041.832.640.54

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-2.020.560.581.04
Placebo-0.080.171.19-0.68

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.030.030.330.37
Placebo0.350.430.050.27

Trials

5 trials available for propofol and Brain Disorders

ArticleYear
Effects of propofol on intracranial pressure and prognosis in patients with severe brain diseases undergoing endotracheal suctioning.
    BMC neurology, 2020, Oct-29, Volume: 20, Issue:1

    Topics: Adult; Brain Diseases; Female; Glasgow Outcome Scale; Humans; Hypnotics and Sedatives; Intracranial

2020
Comparison of the effects of sevoflurane and propofol on cooling and rewarming during deliberate mild hypothermia for neurosurgery.
    British journal of anaesthesia, 2003, Volume: 90, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Anesthesia; Anesthetics, Inhalation; Anesthetics, Intravenous; Bl

2003
End-tidal carbon dioxide monitoring stabilized hemodynamic changes during ECT.
    The journal of ECT, 2003, Volume: 19, Issue:1

    Topics: Adult; Aged; Anesthetics, Intravenous; Brain; Brain Diseases; Carbon Dioxide; Electroconvulsive Ther

2003
Cerebral physiologic effects of burst suppression doses of propofol during nonpulsatile cardiopulmonary bypass. CNS Subgroup of McSPI.
    Anesthesia and analgesia, 1995, Volume: 81, Issue:3

    Topics: Aged; Body Temperature; Brain; Brain Diseases; Cardiopulmonary Bypass; Dose-Response Relationship, D

1995
Ineffectiveness of burst suppression therapy in mitigating perioperative cerebrovascular dysfunction. Multicenter Study of Perioperative Ischemia (McSPI) Research Group.
    Anesthesiology, 1999, Volume: 90, Issue:5

    Topics: Adult; Aged; Animals; Brain Diseases; Electroencephalography; Female; Heart Valves; Hemodynamics; Hu

1999

Other Studies

17 other studies available for propofol and Brain Disorders

ArticleYear
Intraoperative hand strength as an indicator of consciousness during awake craniotomy: a prospective, observational study.
    Scientific reports, 2022, 01-07, Volume: 12, Issue:1

    Topics: Adult; Aged; Anesthetics, Intravenous; Brain Diseases; Consciousness; Craniotomy; Female; Hand; Hand

2022
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
    Revista espanola de anestesiologia y reanimacion, 2015, Volume: 62, Issue:5

    Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B

2015
Mechanisms of propofol attenuation of ketamine-induced neonatal brain injury.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:1

    Topics: Anesthetics, Intravenous; Animals; Apoptosis; Brain Diseases; Cognition Disorders; Disease Models, A

2016
Evaluation of putative inhibitors of mitochondrial permeability transition for brain disorders--specificity vs. toxicity.
    Experimental neurology, 2009, Volume: 218, Issue:2

    Topics: Amino Acid Isomerases; Animals; Boron Compounds; Brain; Brain Diseases; Calcium; Cyclophilins; Dose-

2009
Propofol inhibits aquaporin 4 expression through a protein kinase C-dependent pathway in an astrocyte model of cerebral ischemia/reoxygenation.
    Anesthesia and analgesia, 2009, Volume: 109, Issue:5

    Topics: Animals; Animals, Newborn; Aquaporin 4; Astrocytes; Brain Diseases; Brain Edema; Cell Hypoxia; Cell

2009
Anesthesia during high-field intraoperative magnetic resonance imaging experience with 80 consecutive cases.
    Journal of neurosurgical anesthesiology, 2003, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Androstanols; Anesthesia, Intravenous; Anesthetics, Intravenous; Brain Dise

2003
A moderate dose of propofol and rapidly induced mild hypothermia with extracorporeal lung and heart assist (ECLHA) improve the neurological outcome after prolonged cardiac arrest in dogs.
    Resuscitation, 2006, Volume: 70, Issue:2

    Topics: Anesthetics, Intravenous; Animals; Brain Diseases; Dogs; Female; Heart Arrest; Heart-Assist Devices;

2006
[Electron spin resonance method and brain diseases].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2006, Volume: 128, Issue:5

    Topics: Animals; Antipyrine; Brain Diseases; Edaravone; Electron Spin Resonance Spectroscopy; Free Radical S

2006
Suggested beginning of propofol infusion syndrome in an adult patient without lactacidosis: a case report.
    European journal of anaesthesiology, 2008, Volume: 25, Issue:9

    Topics: Acidosis, Lactic; Adult; Anesthesia, Intravenous; Anesthetics, Intravenous; Brain Diseases; Creatine

2008
[Use of propofol in intracranial surgery in 83 consecutive patients].
    Neuro-Chirurgie, 1994, Volume: 40, Issue:2

    Topics: Adult; Aged; Anesthesia, Intravenous; Brain Diseases; Brain Neoplasms; Female; Hemodynamics; Humans;

1994
Effects of propofol on alterations of multineuronal activity of limbic and mesencephalic structures and neurological deficit elicited by acute global cerebral ischemia.
    Archives of medical research, 1995,Winter, Volume: 26, Issue:4

    Topics: Acute Disease; Animals; Antioxidants; Brain Diseases; Brain Ischemia; Cats; Limbic System; Mesenceph

1995
[Hormonal, immune and metabolic status in intraoperative injury in the course of electrical stimulation with propofol].
    Klinichna khirurhiia, 1999, Issue:3

    Topics: Adult; Anesthetics, Intravenous; Brain; Brain Diseases; Electric Stimulation; Hemodynamics; Humans;

1999
The effects of propofol on brain electrical activity, neurologic outcome, and neuronal damage following incomplete ischemia in rats.
    Anesthesiology, 1992, Volume: 76, Issue:2

    Topics: Animals; Brain; Brain Damage, Chronic; Brain Diseases; Brain Ischemia; Depression, Chemical; Electro

1992
[Propofol in single bolus for treatment of elevated intracranial hypertension].
    Minerva anestesiologica, 1991, Volume: 57, Issue:6

    Topics: Adolescent; Adult; Blood Pressure; Brain Diseases; Cerebrovascular Circulation; Female; Humans; Intr

1991
Total intravenous anaesthesia in stereotactic surgery--one year's clinical experience.
    European journal of anaesthesiology, 1991, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Anesthesia, Intravenous; Blood Pressure; Brain Diseases; Catheterization, Periphe

1991
[Total intravenous anesthesia with propofol-fentanyl in patients undergoing neurosurgery].
    Minerva anestesiologica, 1990, Volume: 56, Issue:9

    Topics: Adult; Aged; Anesthesia, Intravenous; Brain Diseases; Electroencephalography; Electromyography; Fema

1990
[Effects of propofol (diprivan) on intracranial pressure. Preliminary controlled study versus thiopentone].
    Minerva anestesiologica, 1987, Volume: 53, Issue:5

    Topics: Anesthesia, Intravenous; Anesthetics; Brain Diseases; Drug Administration Schedule; Female; Hemodyna

1987